Vaccines targeting lethal and multi-resistant bacteria
Discover and develop safe and effective vaccines to overcome infectious challenges threatening global public health
A world free of suffering from infectious diseases
Proxi Biotech offers best in class technology for creating next generation vaccine antigens targeting bacterial infections
Antimicrobial resistance (AMR) is one of the world's most pressing medical problems. More than 700,000 people die each year from infections resistant to antibiotics. By 2050, such infections are expected to kill 10,000,000 people.
Proxi Biotech, an early stage spin-off from Staten Serum Institute, has developed the BID Technology for detoxification of bacterial toxins. BID Technology replaces the conventional cross-reacting agents in the development of new antigens for toxoid-based vaccines that are highly needed to overcome the AMR challenge.